Atelerix Raises Seed Funding Round

Atelerix, a Cambridge and Newcastle, UK-based spin-out from the University of Newcastle and creators of an innovative cell encapsulation technology, closed a round of funding of undisclosed amount.

The round was led by UK Innovation & Science Seed Fund (UKI2S), formerly known as Rainbow Seed Fund, and new investors including Newable Private Investing and Oxford Technology Management. In conjunction with the funding, Dr. Andrew Muir of UKI2S, has joined the board of Atelerix.

The company intends to use the funds to bring its cell storage products to market.

Led by CEO Mick McLean and Professor Che Connon, scientific founder, Atelerix is commercializing hydrogel technology for the storage and transport of viable cells including stem cells and cell-based assays at ambient temperatures. The technology is used to assist companies that sell cells and tissues, use cells and tissues to discover and test new drugs and develop cell therapies, and companies that store stem cells.

For more information on Funds, visit


 Newable Ventures Limited (FRN 795277) is an Appointed Representative of Larpent Newton & Co Ltd. Larpent Newton & Co Ltd is authorised and regulated by the Financial Conduct Authority, FRN 141275.
Neither Newable Capital Limited nor Newable Private Investing Limited are Authorised and Regulated by the Financial Conduct Authority. Risk warning: Your capital is at risk. Investing in early stage companies involves risks including loss of capital, illiquidity, lack of dividends and dilution. Newable Ventures Limited does not give tax or investment advice.
The availability of tax relief depends on individual investors’ circumstances, and on investee companies’ qualifying status, both of which may be subject to change. If you are in doubt about eligibility for tax reliefs or the tax treatment of your investment, you should seek independent tax advice.